Here are the average weight loss results based on the dose and timeline: 1 mg: 7.2% in 24 weeks and 8.7% in 48 weeks 4 mg: 12.9% in 24 weeks and 16.3% in 48 weeks 8 mg: 17.3% in 24 weeks and 23.9% in 48 weeks 12 mg: 17.5% in 24 weeks and 24.2% in 48 weeks Placebo: 1.6% in 24 weeks and 2.1% in 48 weeks The retatrutide clinical trials are still ongoing, with a phase IV planned after the current phase III
Lembke says
More Recent Semaglutide Trials Recently, 2,000 people with a BMI over 30 who were not diagnosed with diabetes took part in a double-blind trial
Tirzepatide, a dual GIP/GLP-1 agonist, is available under two brand names: Mounjaro and Zepbound
This protective mechanism can temporarily halt ovulation and menstruation
It can cause gastrointestinal side effects such as nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reflux